A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs NBTXR 3 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Nanobiotix
- 04 Apr 2017 Preliminary safety and feasibility data from this trial is expected in H2 2017, according to a Nanobiotix media release.
- 31 May 2016 Status changed from planning to not yet recruiting, according to a Nanobiotix media release.
- 29 Apr 2016 According to Nanobiotix media release, Nanobiotix received approval from the US Food and Drug Administration (FDA) for the Company's Investigational New Drug (IND) application on December 30, 2015 (announced January 2016). Company also plans to initiate this study in the US in 2016.